Sequencing of Ipilimumab+Nivolumab and Encorafenib+Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
J. Clin. Oncol 2022 Sep 01;[EPub Ahead of Print], PA Ascierto, M Mandalà, PF Ferrucci, M Guidoboni, P Rutkowski, V Ferraresi, A Arance, M Guida, E Maiello, H Gogas, E Richtig, MT Fierro, C Lebbè, H Helgadottir, P Queirolo, F Spagnolo, M Tucci, M Del Vecchio, M Gonzales Cao, AM Minisini, S De Placido, MF Sanmamed, D Mallardo, M Curvietto, I Melero, G Palmieri, AM Grimaldi, D Giannarelli, R Dummer, V Chiarion SileniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.